PharmaFocus Today – Page 3 – media

Today, Hisun Pharmaceuticals has two pieces of good news.

Recently , Hisun Pharmaceutical surprised the market with two pieces of good news: its net profit for the first quarter of 2026 is expected to increase by 923% to 1095% year-on-year, which is close to twice the net profit of RMB 260 million for the whole of 2025; at the same time, Hisun Pharmaceutical officially announced a licensing cooperation with pharmaceutical giant AbbVie for Nav1.8 inhibitors with a total value of up to US$745 million . >>The Logic Behind the Explosive Growth in Performance Hisun Pharmaceutical expects to achieve a net profit attributable to shareholders of RMB 477 million to RMB 557 million in the first quarter, nearly double its net profit for the entire year of 2025 (RMB 260 million). The core drivers of this surge in performance are twofold: first, the continued strong sales of innovative products such as propofol and cogglitazone, resulting in significant market expansion success; ...
- Source: drugdu
- 56
- April 15, 2026
Established players are increasing their investment in the ASO (App Store Optimization) track.

Alloy Therapeutics recently announced a collaboration and licensing agreement with Biogen, authorizing Biogen to use Alloy’s novel and proprietary AntiClastic™ antisense oligonucleotide (ASO) platform to advance antisense therapies targeting multiple undisclosed targets. Alloy will receive an upfront payment and will be eligible for additional milestone payments and tiered royalties based on any products generated from the collaboration. It is worth noting that Biogen has been deeply involved in the ASO field for many years and has the blockbuster ASO drug Spinraza in hand. This time, choosing to use an external platform to promote the development of the next-generation ASO pipeline is both an endorsement of the Alloy technology platform and an expectation for the next generation of ASO drugs. 01 Biogen’s anxiety In 2025, Boquan’s annual revenue was $9.9 billion, failing to break the $10 billion mark for the third consecutive year, and far from its peak of $14.38 billion ...
- Source: drugdu
- 58
- April 15, 2026
A long-established pharmaceutical company saw its Q1 net profit surge by 985%.

Recently, Wanbangde Pharmaceutical released its performance forecast, showing that it expects to achieve a net profit attributable to the parent company of 165 million yuan in the first quarter of 2026, an increase of 985.40% compared with 15.2018 million yuan in the same period last year ; even more impressive is the net profit excluding non-recurring items, which reached 164 million yuan, while the same period last year was a loss of 7.9053 million yuan, a year-on-year increase of 2174.55% . This performance stands in stark contrast to the company’s 2025 results. According to the company’s previously disclosed preliminary 2025 financial report, Wanbangde’s revenue for the entire year was 1.145 billion yuan, a year-on-year decrease of 20.69%; net profit attributable to the parent company was a loss of 199 million yuan, a significant decrease of 458.54% compared to 55.441 million yuan in the same period of the previous year. The ...
- Source: drugdu
- 59
- April 14, 2026
Domestic Companies Account for 9 Spots, Foreign Companies Only Have 1 Product

Roxadustat capsules from FibroGen (China) . In terms of specific sales figures, Ametinib Mesylate tablets topped the list with sales of 5.53 billion yuan , far ahead of the competition, followed by Vometinib Mesylate tablets with 3.757 billion yuan . The threshold for the top ten has risen to 1.7 billion yuan, with total sales exceeding 26.5 billion yuan. Domestic companies such as Hengrui Medicine, BeiGene, Hansoh Pharmaceutical, Allis, Simcere Pharmaceutical, and Akeso Biopharma are the main players on the list, demonstrating the vigorous vitality of pharmaceutical innovation in China. Note: The products listed in this article are Class 1 innovative drugs approved for marketing in 2016 for chemical drugs and 2020 for traditional Chinese medicine and biological products. Sales data cover the three major terminal markets of domestic hospitals, retail and e-commerce. 01 Domestic innovative drugs account for 9 seats The 2025 list of the top 10 innovative drugs ...
- Source: drugdu
- 58
- April 14, 2026
Merck’s first oral PCSK9 lipid-lowering drug, a “trump card,” is about to hit the market.

Low-density lipoprotein cholesterol (LDL-C) is also known as “bad cholesterol.” Elevated LDL-C levels can lead to hypercholesterolemia, a condition that often further contributes to the formation of arterial plaques. Data from the New England Journal of Medicine (NEJM) shows that excessively high LDL-C levels increase the global risk of death from chronic diseases by 6.4 times, making it arguably the “most insidious threat to life.” On April 8, 2026, Merck officially announced that it had presented detailed Phase III data for its oral PCSK9 inhibitor Enlicitide (MK-0616) CORALreef AddOn at the 2026 American College of Cardiology (ACC) Annual Meeting. The results were simultaneously published in the *Journal of the American College of Cardiology* ( JACC ) . As the world’s first oral PCSK9 inhibitor to enter Phase III clinical trials, this drug demonstrated overwhelming superiority in head-to-head trials, potentially ending the “injection era” for this target . picture According to ...
- Source: drugdu
- 69
- April 14, 2026
Industry News | Easily Viagra® (Demozimab) Approved in China for the Treatment of Adult Patients with Chronic Sinusitis and Nasal Polyps

• Easily Reliable® is China’s first and currently only ultra-long-acting biological agent for the treatment of chronic sinusitis with nasal polyps. This approval is based on the results of the ANCHOR clinical trial, which showed that Easily Relief® achieved clinically and statistically significant improvements in reducing nasal polyps and alleviating nasal congestion symptoms. • Patients with chronic sinusitis and nasal polyps experience persistent symptoms that significantly impact their daily lives, creating an urgent need for novel treatment options. GlaxoSmithKline (LSE/NYSE: GSK) today announced that the China National Medical Products Administration (NMPA) has approved EasilyLikeli® ( demozimab) in combination with nasal corticosteroids for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) whose disease is not adequately controlled by systemic corticosteroids and/or surgery. These patients have not achieved adequate disease control despite receiving systemic corticosteroids and/or surgery. The NMPA also recently approved EasilyLikeli® for maintenance therapy in adults ...
- Source: drugdu
- 51
- April 14, 2026
Merck/Daiichi Sankyo’s B7-H3 ADC has been granted Priority Review designation by the FDA for small cell lung cancer.

On April 13, Daiichi Sankyo and Merck jointly announced that their Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review status by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after prior platinum-based chemotherapy. The Prescription Drug User Fee Act (PDUFA) expires on October 10, 2026.Ifinatamab deruxtecan is a potential first-in-class antibody-drug conjugate (ADC) targeting B7-H3, specifically designed by Daiichi Sankyo. In October 2023, Daiichi Sankyo and Merck entered into a global co-development agreement excluding Japan. This BLA submission is primarily based on the results of the IDeate-Lung01 Phase II clinical trial and is supported by data from the IDeate-PanTumor01 Phase I/II trial. Regarding the IDeate-Lung01 trial IDeate-Lung01 is a global, multicenter, randomized, open-label, split-part Phase II trial designed to evaluate the safety and efficacy of ifinatamab deruxtecan ...
- Source: drugdu
- 81
- April 14, 2026
Pancreatic Cancer Drug Phase III Study Succeeds

On April 13, Revolution Medicines announced that the Phase III RASolute 302 study of Daraxonrasib (RMC-6236) for pancreatic ductal adenocarcinoma (PDAC) achieved positive results in an interim analysis. Daraxonrasib is an investigational oral RAS(ON) multi-selective non-covalent inhibitor independently developed by Revolution Medicines, designed to inhibit the interaction between wild-type and mutant RAS(ON) proteins and their downstream effectors, suppressing RAS signaling, thereby treating cancers driven by various common RAS mutations, including PDAC, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The drug has received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA for the treatment of previously treated metastatic PDAC patients with G12 mutations. Additionally, Daraxonrasib has been included in the FDA Commissioner’s National Priority Review Voucher Pilot Program, expected to accelerate its market approval. Revolution Medicines has invested tremendous effort in this drug, raising $2 billion in June 2025 solely to advance its global development and commercialization ...
- Source: drugdu
- 68
- April 14, 2026
CATL, Zhiyuan, and Galaxy General Join Forces in Bet! Blue Dot Touch Announces Completion of Over 100 Million Yuan C+ Round Financing

Blue Dot Touch, a leading domestic six-dimensional force sensor company, announced on April 13 that it has completed a C+ round financing of over 100 million yuan. This round of financing was jointly invested by industry and well-known institutions including Puquan Capital under CATL, Zhiyuan Robot, Galaxy General, Opt, and Galaxy Source Convergence. So far, Blue Dot Touch has completed multiple rounds of hundred-million-yuan financing, and its shareholder lineup also includes top-tier capital such as Sequoia China, GF Xinde, Fosun Creation, and Zhuhai Technology Industry Group. It is expected to become the first stock in the robotic force sensor field. Liu Wuyue, founder and CEO of Blue Dot Touch, stated in an interview with Shanghai Securities News that this round of financing will help the company focus on the research and development of next-generation high-precision, high-integration force control sensors, better meeting the urgent needs of humanoid robot mass production; simultaneously ...
- Source: drugdu
- 58
- April 14, 2026
Dongyangguang Pharmaceutical’s Class 2 new drug, with a market capitalization exceeding 1 billion yuan, is coming soon.

Recently, the National Medical Products Administration (NMPA) accepted the marketing authorization application (NDA) for Dongyangguang Pharmaceutical’s independently developed improved new drug, vonoprazan fumarate sodium chloride injection (hereinafter referred to as “vonoprazan injection”), for the treatment of peptic ulcer bleeding. Gastrointestinal ulcer bleeding is a common complication of peptic ulcer disease, with a mortality rate of 4% to 10%, posing a significant risk. Effectively inhibiting gastric acid secretion is a key strategy for treating peptic ulcer bleeding and alleviating symptoms. Currently, proton pump inhibitors (PPIs) are the first-line drugs for acid suppression therapy in clinical practice in my country. However, in recent years, potassium-competitive acid blockers (P-CABs) have quietly emerged, providing a powerful “new weapon” for the treatment of acid-related diseases and Helicobacter pylori infection. Compared with PPIs, P-CABs have advantages in pharmacodynamics and pharmacokinetics. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) that reversibly binds to the K+ binding site ...
- Source: drugdu
- 75
- April 13, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.